drugset
drugset / Trial / NCT00078806

Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis

NCT00078806 ↗

Phase 3 Terminated 19 enrolled Amgen Immunex Corporation · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study was to determine the efficacy of etanercept in pediatric patients with systemically active system onset juvenile rheumatoid arthritis (SOJRA).

Timeline

Start
2001-06-04
Primary completion
2004-05-06
Completion
2004-05-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 0.4 mg/kg Subcutaneous
Subject Etanercept Protein / enzyme biologic 0.8 mg/kg Subcutaneous

Indications

juvenile idiopathic arthritis